COMPASS Pathways plc (CMPS)

About COMPASS Pathways plc

Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.

As of November 3, 2026, COMPASS Pathways plc (CMPS) stock tumbled to $8.41, down 27.31% (-$3.16) versus the previous close. On the day, shares have traded between $7.54 and $11.76. That puts CMPS in the lower third of its 52-week range of $4.88 to $15.87. COMPASS Pathways plc operates in the pharmaceutical preparations space and carries a market capitalization of roughly $1.60 billion, with about 16.85 million shares changing hands.

Latest CMPS news

• Compass Pathways To Complete COMP360 FDA Filing Within Two Weeks — CEO Nath Eyes Launch In First Half Of 2027stocktwits.com· Nov 3, 8:00 AM ET
• Compass Pathways Announces Third Quarter 2026 Financial Results and Business HighlightsYahoo Finance· Nov 3, 6:30 AM ET
• CMPS, HELP Stocks On Track For Worst Day In Months On Competitive FDA Psychedelic Race Fearsstocktwits.com· Nov 2, 2:57 PM ET
• New Joint Survey from Compass Pathways and the Depression and Bipolar Support Alliance Reveals the Lived Burden of Treatment-Resistant Depression on Patients and CaregiversYahoo Finance· Nov 2, 6:30 AM ETDBSA
• 1 Reason Compass Pathways Is Worth a Second Look This Monthfool.com· Nov 2, 3:50 AM ET
• COMPASS Pathways (CMPS) Could Be 50% Below Fair Value After NEI Congress FocusYahoo Finance· Oct 29, 1:22 AM ET
• Compass Pathways to Highlight Scientific Research and TRD Disease State Education Efforts at the 2026 Neuroscience Education Institute Fall CongressYahoo Finance· Oct 28, 6:30 AM ETNEI
• Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026Yahoo Finance· Oct 27, 6:30 AM ET

Source: Yahoo Finance RSS · Updated November 3, 2026

Want CMPS headlines, alerts and AI research in one place? Create a free account →

• $HELP Best in class. $CMPS filling NDA in few weeks. Maybe Helus Phase 3 data before them .

  @BoiBiotech· Nov 3, 8:44 AM ET· Bullish

• $CMPS My only regret is not having more to invest while it's under $10

  @sonofyama· Nov 3, 8:42 AM ET· Bullish

• $CMPS they’re in the zone this team is LOCKED IN!!

  @Canvasback33· Nov 3, 8:37 AM ET· Bullish

• $CMPS market’s not even valuing the pipeline that sits behind this launch. In it for the long haul, especially with LE at the helm.

  @BobWill· Nov 3, 8:28 AM ET· Bullish

• $CMPS congrats to whomever/whatever group executed yesterdays attack. Well executed. I’m guessing you’re on the call ….cover.

  @Canvasback33· Nov 3, 8:27 AM ET· Bullish

Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →